Contrasting effects of cPLA2 on epithelial Na+ transport

Roger T. Worrell1, Hui-Fang Bao1, Don D. Denson2, and Douglas C. Eaton1

Departments of 1 Physiology and 2 Anesthesiology, Center for Cell and Molecular Signaling, Emory University, Atlanta, Georgia 30322


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Activity of the epithelial Na+ channel (ENaC) is the limiting step for discretionary Na+ reabsorption in the cortical collecting duct. Xenopus laevis kidney A6 cells were used to investigate the effects of cytosolic phospholipase A2 (cPLA2) activity on Na+ transport. Application of aristolochic acid, a cPLA2 inhibitor, to the apical membrane of monolayers produced a decrease in apical [3H]arachidonic acid (AA) release and led to an approximate twofold increase in transepithelial Na+ current. Increased current was abolished by the nonmetabolized AA analog 5,8,11,14-eicosatetraynoic acid (ETYA), suggesting that AA, rather than one of its metabolic products, affected current. In single channel studies, ETYA produced a decrease in ENaC open probability. This suggests that cPLA2 is tonically active in A6 cells and that the end effect of liberated AA at the apical membrane is to reduce Na+ transport via actions on ENaC. In contrast, aristolochic acid applied basolaterally inhibited current, and the effect was not reversed by ETYA. Basolateral application of the cyclooxygenase inhibitor ibuprofen also inhibited current. Both effects were reversed by prostaglandin E2 (PGE2). This suggests that cPLA2 activity and free AA, which is metabolized to PGE2, are necessary to support transport. This study supports the fine-tuning of Na+ transport and reabsorption through the regulation of free AA and AA metabolism.

sodium reabsorption; arachidonic acid; cyclooxygenase; A6 cells; cytosolic phospholipase A2


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

TRANSPORT OF SODIUM ACROSS principal cells in the distal collecting duct of the kidney is via an apical amiloride-sensitive epithelial Na+ channel (ENaC) and a coupled basolateral Na+-K+-ATPase. This system vectorially moves Na+ from the external environment to the organism's internal environment. The rate-limiting step for this process is by regulation of ENaC. The principal means of regulating Na+ transport in the cortical collecting duct is hormonal via the mineralocorticoid, aldosterone, and the peptide, antidiuretic hormone (19, 21, 40). Both hormones increase the apical membrane conductance to Na+, thereby promoting Na+ reabsorption. Much effort has been focused on understanding the cellular mechanism of these hormonal regulatory events; however, the intracellular mechanism(s) responsible for their effects are not well identified. Less well described are the mechanisms of fine-tuning and local, intratubular, or cellular control of Na+ uptake.

Phospholipase A2, arachidonic acid, and ion channels. The phospholipases A2 (PLA2) are a family of enzymes that metabolize membrane phospholipids and are generally classified into three groups, secretory (sPLA2), Ca2+ independent, and cytosolic PLA2 (cPLA2) (33). Although the latter was originally termed cytosolic because it is found in the cytosol, this term is somewhat misleading because the active form of cPLA2 is membrane associated. cPLA2 has long been recognized to play an important role in a number of cellular processes. cPLA2 hydrolyzes the sn-2 position of phospholipids, resulting in the release of free fatty acids, primarily arachidonic acid (AA) in eukaryotic cells, and lysophospholipids. Both the free fatty acids and the lysophospholipids then may themselves mediate a number of responses by both intracellular and extracellular signaling. It is also well documented that a variety of plasma membrane receptors act on PLA2 (5, 33). Upon release, AA may initiate signaling or can be metabolized into a wide range of signaling factors by cyclooxygenases, lipoxygenases, and cytochrome P-450 monooxygenases, producing a cascade of prostaglandins, leukotrienes, and monooxygenase products, respectively. Determined by the predominate active metabolic pathways, the release of AA produces a prodigiously diverse range of physiological and pathological effects. In particular, many ion channels are affected by either AA itself and/or the various metabolites of AA (31). Free unsaturated fatty acids, principally AA, have varying effects on ion channels, thus a priori, the effects of AA on a given ion channel cannot be guessed. The effects of AA can either be inhibitory (23) or stimulatory (11, 13, 39). In addition, many studies involving the addition of free AA, usually at concentrations exceeding normal physiological levels, may not adequately address the physiological role of AA or its metabolites on ion transport.

In the 1970s, it was suggested that Na+ reabsorption in the toad bladder was associated with an increased turnover of phospholipids (22), most likely through the involvement of PLA (42). To determine the possible effects of phospholipid turnover, and, in particular, AA on amiloride-sensitive Na+ channels and transepithelial Na+ reabsorption, we chose to manipulate free AA levels by altering cPLA2 activity, using aristolochic acid as a relatively selective inhibitor of cytosolic PLA2, a strategy that had proved effective in previous work involving the maxi-K+ channel in GH3 cells (13, 14).

This paper demonstrates that cPLA2 is tonically active in transporting A6 cells and that this activity is necessary for the support of transepithelial transport. Interestingly, AA is shown to reduce Na+ transport, whereas the metabolic product of AA, prostaglandin E2 (PGE2), is found to be necessary to maintain normal transport. Furthermore, the sidedness of cPLA2 inhibition suggests there is a local apical membrane-associated pool of cPLA2 at or near the apical Na+ channel in addition to the perinuclear and endoplasmic reticular localization of cPLA2.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cell culture. The 2F3 clonal line of A6 cells or A6 cells were grown on permeable supports under conditions that have been demonstrated to produce transepithelial Na+ transport, as well as a predominance of the low-conductance highly selective amiloride-sensitive Na+ channel in the apical membrane (21). Open-circuit current measurements were made using the 2F3 clonal cell line (which, in general, produces more current than the A6 cell line). Short-circuit current and single channel measurements were made using the A6 cell line. It should be noted that A6 cells were found to respond identically to the 2F3 cell line in open-circuit current measurements, albeit with a lower magnitude of current. Cells were maintained at 26°C in 4% CO2 in a mixture of 7:3 Coon's F-12 and Leibovitz's L-15 with 25 mM NaHCO3 (pH 7.4), 10% fetal calf serum, 1% streptomycin, and 0.6% penicillin. Cells for transepithelial current measurements and assays involving free AA production or cPLA2 activity were grown on 25-mm Anapore supports (Nunc). Cells for patch-clamp analysis were plated on rat tail collagen-coated Millipore-CM filters attached to the bottom of custom-made Lucite rings. Cells on both types of permeable supports were grown to confluency in the above conditions in the presence of 1.5 µM aldosterone. Under these conditions, high-resistance monolayers formed within 7-14 days. Short-circuit current measurements were performed on A6 cells grown under the conditions reported by Blazer-Yost et al. (4).

Measurement of transepithelial current. The quality of high-resistance monolayer formation was monitored using an epithelial voltohmmeter (EVOM; World Precision Instruments). This instrument consists of a pair of Ag-AgCl electrodes mounted in "chopstick" fashion attached to a customized voltohmmeter. Both transepithelial potential (in mV) and transepithelial resistance (in KOmega ) were measured with this instrument. Transepithelial current was calculated by Ohm's law, expressed as µA/cm2, and is referred to as open-circuit current in the text to clearly distinguish it from the short-circuit currents measured in Ussing chambers. Although the open-circuit current technique tends to underestimate the amount of current that would be obtained in short-circuit current measurements, EVOM measurements proved consistent and reliable for detecting changes in transepithelial voltage, resistance, and current. Because cells used in EVOM measurements were at room temperature and not aerated with 95:5 gas, current tended to slowly decline with time (see Figs. 1A and 7A). Experiments were performed in serum-free A6 culture media. Upon replacement of serum- containing media with serum-free media, currents typically become relatively stable within 5 min. To corroborate open-circuit current measurements, conventional short-circuit current measurements were performed. A6 cells were grown to confluency on Transwell supports, and the supporting membrane was then placed in an Ussing chamber for measurement of short-circuit current as described by Blazer-Yost et al. (3). Current from individual monolayers was allowed to stabilize (~1-2 h) before drug addition. Data were recorded on a strip chart recorder, and current magnitudes were subsequently measured for plotting. No qualitative difference was observed between the methods of measurement or the cell line used (2F3 vs. A6).


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of cytosolic phospholipase A2 (cPLA2) from the apical side increases transepithelial Na+ transport. A: open-circuit transepithelial current measurement with apical application of the cPLA2 inhibitor, aristolochic acid (200 µM; black-down-triangle ), and transepithelial currents from control monolayers () are shown. Inhibition of cPLA2 from the apical side increased transepithelial current ~2-fold within 1 min (P < 0.001). B: effect of apical addition of aristolochic acid is fully reversible. Relative transepithelial current with addition of aristolochic acid to the apical side (time 0) followed by washout (Wash) of aristolochic acid (arrow, at 3 min) is shown. Relative current after washout was not significantly different from control current. For each group of 2F3 cells, n = 12.

AA efflux. A commonly used indirect approach to assess the release of free AA involves monitoring the release of [3H]AA from cells (1). A6 cells on permeable supports were loaded with [3H]AA for 24 h. During this time, the [3H]AA was incorporated into the cellular lipids. Cells were then washed four times in PBS, and the efflux of labeled AA was monitored by a standard sample-and-replace method using fatty acid-free BSA in the efflux media to act as a trap for liberated free fatty acid. Samples were placed in scintillation cocktail (BioSafe II; Amersham), and radioactive decay was counted using a Packard 1900A scintillation counter. At the end of the sample period, cells were lysed in 0.1 N NaOH, and the cell lysate was counted to determine the counts remaining in the cells. Data were plotted as the percent counts remaining in the cells for each time point, and the slope of the relation was used to determine the relative rate of free AA release. This technique offers an advantage over PLA2 activity measurements in cell lysates in that efflux (AA release) can be monitored on the apical side of the monolayer, thus providing a more accurate assessment of the free AA at the apical membrane.

Single channel patch-clamp recording. Cell-attached single channel patch data of ENaC were obtained as previously described by Kemendy et al. (25) and Ma and Ling (29). Briefly, A6 cells were cultured on custom Lucite rings and viewed under Hoffman modulation optics mounted on a Nikon Diaphot inverted microscope. Patch pipettes with a tip resistance of 7-9 MOmega were fabricated from TW150 glass on a Narishige PP-83 puller and fire-polished with a Narishige MF-83 polisher. Bath and pipette solutions contained (in mM): 96 NaCl, 3.4 KCl, 0.8 CaCl2, 0.8 MgCl2, and 10 HEPES at pH 7.4 (titrated with 1 N NaOH). Single channel currents from apical membrane patches were recorded with an Axon 1D amplifier and data digitized to a computer using a TL-1 data interface. Single channel data analysis was accomplished using pCLAMP software (Axon).

Reagents. [3H]AA was obtained from Amersham. Aristolochic acid, ibuprofen, 5,8,11,14-eicosatetraynoic acid (ETYA), 7,7-dimethyleicosadienoic acid (DEDA), and PGE2 were obtained from Biomol. All other reagents were obtained from either GIBCO BRL or Sigma.

Significance tests. Data are presented as means ± SE. Significance was estimated using the Student's t-test with P < 0.05 indicating a significant difference.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Inhibition of cPLA2 by application of the cPLA2 inhibitor, aristolochic acid, produced opposite effects depending on whether application was to the apical or basolateral side of the transporting epithelial monolayer. We show (below) that inhibition of cPLA2 from the apical side produces an increase in transepithelial current, whereas inhibition from the basolateral side produces an inhibition of transepithelial current. The apical effect is due to the downmodulation of apical Na+ channels (ENaC) by free AA produced by cPLA2 activity. Current inhibition after inhibition of cPLA2 from the basolateral side results predominately from an inhibition of PGE2 production within the cells. It is important to note that both results imply that cPLA2 is present and active in the aldosterone-stimulated monolayers and that disruption of cPLA2 activity has significant effects on the magnitude of transepithelial Na+ transport.

Inhibition of cPLA2 from the apical side. The results of cPLA2 inhibition after apical application of aristolochic acid is shown in Fig. 1. Open-circuit transepithelial current shows a marked increase on application of aristolochic acid to the apical surface. Current was 6.8 ± 0.2 µA/cm2 in the control monolayers and 7.5 ± 0.3 µA/cm2 in the treated group at time zero. With the addition of an apical media containing 200 µM aristolochic acid, current increased significantly within 1 min to 13.6 ± 0.6 µA/cm2 (P < 0.001; Fig. 1A). Addition of replacement apical media to the control group resulted in no significant change in current. Currents remained elevated approximately twofold for at least 5 min, with control and aristolochic acid-treated groups having currents of 5.6 ± 0.2 and 13.6 ± 0.5 µA/cm2, respectively. Apical aristolochic acid reduced transepithelial resistance from 1.22 ± 0.09 KOmega in control to 0.95 ± 0.06 KOmega . The increase in current with apical aristolochic acid was fully reversible, as shown in Fig. 1B. Open-circuit transepithelial current was 5.9 ± 0.2 µA/cm2 before the apical addition of aristolochic acid. Apical aristolochic acid produced an increase in current to 9.6 ± 0.3 µA/cm2. Upon washout of apical aristolochic acid, currents were not significantly different from control, 5.9 ± 0.3 µA/cm2. All current was amiloride sensitive (data not shown).

In an effort to more fully describe the nature of current stimulation seen in the open-circuit current measurements with apical application of aristolochic acid, the short-circuit current method was applied. Identical results to those obtained in open-circuit conditions were observed upon apical application of 200 µM aristolochic acid under short-circuit conditions (Fig. 2). Starting current was 22.7 ± 1.4 µA/cm2 for the control group of monolayers and 20.3 ± 2 µA/cm2 for the treatment group. Current did not vary significantly in the control group over the course of the experiment, with the ending current being 22.7 ± 1.4 µA/cm2. Significant current stimulation was seen with the apical application of aristolochic acid within 20 s of addition (30.8 ± 1.6 µA/cm2, P < 0.001 vs. current at time 0). Current remained elevated during the 3-min time course with current at 40.2 ± 2.9 µA/cm2. The addition of 1 × 10-5 M amiloride to the apical bathing media reduced current in both the control and the aristolochic acid-treated groups, with current being 3.3 ± 1.1 and 3.5 ± 1.3 µA/cm2, respectively. There was no significant difference in the amiloride-insensitive current component between each group.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Short-circuit measurement of transepithelial current with apical application of 200 µM aristolochic acid (black-down-triangle ) and control monolayers (). Apical aristolochic acid application produced a significant change in transepithelial current within 20 s of addition (P < 0.01). Current stimulation saturated at ~2 min. Addition of 1 × 10-5 amiloride (5-min time point) reduced transepithelial current to near 0 both for control and aristolochic acid-treated groups. Currents in control and treated groups after amiloride were not significantly different. For each group of A6 cells, n = 4.

Because there have been some reports that aristolochic acid can affect the activity of sPLA2 (41), a specific inhibitor of sPLA2 was applied to the apical side of transporting monolayers. Figure 3 clearly demonstrates that 10 µM DEDA does not affect open-circuit transepithelial current. Current level began at 7.1 ± 0.2 µA/cm2, and addition of DEDA to the apical side did not significantly increase current; indeed, current was slightly decreased to 6.4 ± 0.3 µA/cm2. However, subsequent application of 100 µM apical aristolochic acid produced a significant increase in transepithelial current (12.5 ± 0.3 µA/cm2, P < 0.001). Thus the apical aristolochic acid effect is not due to actions on sPLA2.


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 3.   Apical application of the secretory PLA2 inhibitor 7,7-dimethyleicosadienoic acid (DEDA) does not change transepithelial current. Apical application of 10 µM DEDA (time 0) produced no significant change in transepithelial open-circuit current, whereas in the same set of monolayers, apical application of the cPLA2 inhibitor aristolochic acid (100 µM, arrow, at 5 min) produced a significant change (P < 0.001). For 2F3 monolayers, n = 12.

Presumably, inhibition of cPLA2 by apical aristolochic acid application should reduce the amount of free AA present at the apical membrane. One means of accessing the liberation of free AA is to measure the release (efflux) of labeled AA from the monolayers. Figure 4A shows the efflux of [3H]AA from monolayers that had [3H]AA incorporated into the cellular lipid pool. Apical application of 200 µM aristolochic acid, as presumed, resulted in a decrease in the release (efflux) of free AA from the apical surface of the transporting monolayers. Although small, the efflux rate of [3H]AA from the apical surface was significantly reduced with apical aristolochic acid application (Fig. 4B). Efflux rates were 0.045 ± 0.013 s-1 for the untreated group and 0.019 ± 0.004 s-1 for monolayers treated with apical aristolochic acid (P < 0.05). It should be mentioned that the actual release of free AA is underestimated by monitoring the efflux of AA, because free AA will partition into the cellular membrane and the cytosol as well as the external media. Nonetheless, a decrease in AA release was observed, thus indicating that available free AA at the apical membrane is reduced by the apical application of aristolochic acid. No appreciable change in [3H]AA efflux was detected with apical application of DEDA or with the basolateral application of aristolochic acid (data not shown).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   Apical application of aristolochic acid reduces apical release of free arachidonic acid. A: apical efflux of free [3H]arachidonic acid ([3H]AA) with apical application of 200 µM aristolochic acid (black-down-triangle , added at arrow) and under control conditions (). Data are presented as the % counts remaining in the cell for each time point. B: mean apical side [3H]AA efflux rates from individual monolayers. Efflux rates are from the 10- to 20-min time interval. Although the efflux rates are small, apical application of aristolochic acid (Arist) produced a significant reduction in the rate of [3H]AA release (*P < 0.05, n = 12 for 2F3 monolayers).

The cPLA2 liberation of free AA from the sn-2 position of membrane lipids results in the production of a lysophospholipid product. Either free AA or the lysophospholipid product may act as a signaling molecule, and, in addition, free AA is the substrate for a number of enzymes and can result in a prodigious number of different signaling molecules. In an effort to ascertain which signaling pathways are involved, an analog of AA containing four triple bonds (ETYA) vs. the four double bonds of AA can be employed. ETYA acts as an unsaturated free fatty acid as well as an inhibitor of the enzymes that normally metabolize free AA. It has thus been used to distinguish between free fatty acid effects and AA metabolic product effects. As shown in Fig. 5, a 2-min apical application of 40 µM ETYA fully reverses the effect of current stimulation with apical application of aristolochic acid, thus implying that free AA is responsible for decreasing transepithelial current. Control currents were 5.7 ± 0.4 µA/cm2, which increased to 9.3 ± 0.7 µA/cm2 with apical application of 200 µM aristolochic acid. Subsequent apical addition of ETYA reduced currents to control values (5.6 ± 0.4 µA/cm2) and increased transepithelial resistance from 0.99 ± 0.05 KOmega to 1.16 ± 0.06 KOmega . Apical application of ETYA on control monolayers resulted in an ~9% reduction of basal current, from 4.3 ± 0.2 to 3.9 ± 0.2 µA/cm2, which did not represent a significant difference (n = 12, data not shown). The lack of significance may arise from the presence of endogenous AA masking the effect of ETYA in the basal state.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 5.   The apical aristolochic acid effect is reversed by apical addition of the unsaturated free fatty acid, 5,8,11,14-eicosatetraynoic acid (ETYA). After apical addition of 200 µM aristolochic acid (time 0), apical addition of 40 µM ETYA (arrow, at 5 min) reduces transepithelial open-circuit current to control levels. Relative current with ETYA was not significantly different from control (n = 6 for 2F3 monolayers).

To determine whether the stimulation of transepithelial current observed with apical application of aristolochic acid in monolayers was due to a free fatty acid-induced reduction in ENaC activity, the patch-clamp technique was employed. Figure 6 shows the results of cell-attached patch-clamp recordings on A6 cells, specifically ENaC activity. Typical single channel records are shown in Fig. 6A. After addition of 40 µM ETYA, the single channel open time decreases. With extensive washout, this decrease in channel open time can be partially reversed. A slight decrease in channel amplitude is also observed; however, this is not due to a change in the single channel conductance, as shown in Fig. 6B, but rather represents a shift in the cell membrane potential, thus affecting the patch-clamp potential (~8 mV). The voltage shift is not sufficient to produce the profound effects on channel open time observed in Fig. 6A. Indeed, channel open time in the presence of ETYA is also decreased from control values if the patch-clamp potential is adjusted such that the channel amplitude remains constant (e.g., a constant patch potential, data not shown). Figure 6C shows the mean results obtained from eight patches. ENaC open probability (Po) was 0.43 ± 0.05 before ETYA and was reduced 56 ± 9% to 0.18 ± 0.04 (P < 0.002) with the application of ETYA. Subsequent washout led to a partial reversal with a mean channel Po of 0.30 ± 0.03%.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   The unsaturated free fatty acid ETYA reduces apical epithelial Na+ channel (ENaC) open probability (Po). A: representative cell-attached single channel recordings in A6 cells of ENaC under control, 40 µM ETYA, and washout conditions. Bath application of ETYA reduces the amount of time the channel spends in the open state. This effect is partially reversible on washout of the ETYA from the bath. B: current-voltage relations of ENaC in the presence and absence of ETYA. The apparent reduction in single channel amplitude with ETYA observed in A does not represent a change in single channel conductance (slope of relation, see text for details). C: ENaC Po from 8 patches similar to those in A. Bath application of 40 µM ETYA results in a 52% reduction in Po (*P < 0.01). This reduction in ENaC Po is partially reversible on ETYA washout (#P < 0.05 vs. ETYA treated).

Inhibition of cPLA2 from the basolateral side. Unlike the results of cPLA2 inhibition from the apical side of the monolayer, basolateral application of aristolochic acid produced a decrease in transepithelial current.1 Figure 7A shows the results of basolateral application of 200 µM aristolochic acid on open-circuit current. Relative current is plotted. Starting current amplitude was 5.2 ± 0.09 µA/cm2 for both the control and treatment groups. The replacement of basolateral media results in a slow rundown of transepithelial current, with current being reduced to 3.1 ± 0.1 µA/cm2 after 20 min. The inclusion of aristolochic acid in the basolateral media results in a significant decrease (over control) in transepithelial current. The decrease over control is first noted and significant (P < 0.05) at ~3 min and continues to develop for the 20-min time course presented. The time course is thus slower than that of the apical effect shown in Fig. 1A that was complete at 1 min. Currents at the 5-min time point were 4.7 ± 0.1 µA/cm2 for control and 3.7 ± 0.1 µA/cm2 for basolateral aristolochic acid. This difference was greater at the 20-min time point where currents were 3.1 ± 0.1 and 1.3 ± 0.08 µA/cm2 for control and basolateral aristolochic acid-treated groups, respectively. Transepithelial resistance rose from 1.29 ± 0.07 KOmega control to 1.56 ± 0.08 KOmega at the 15-min time point.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 7.   Inhibition of cPLA2 from basolateral side inhibits transepithelial Na+ transport. A: open-circuit transepithelial current measurement with basolateral application of the cPLA2 inhibitor aristolochic acid (200 µM; black-down-triangle ). Relative transepithelial currents from control monolayers are shown (). Inhibition of cPLA2 from the basolateral side inhibited transepithelial current beginning at 2 min and reaching maximal inhibition at ~15 min (P < 0.001 vs. control, 15-min time point for each, n = 12 for 2F3 cell monolayers). Under open-circuit current measurement conditions used, control currents showed some degree of decline within the observation time period (see MATERIALS AND METHODS). Current at time 0 was ~7 µA/cm2. B: effect of basolateral addition of aristolochic acid is not reversed by basolateral application of ETYA. Relative transepithelial current with the addition of aristolochic acid to the basolateral side (time 0) followed by basolateral application of ETYA (arrow, at 10 min). Relative current was reduced further by basolateral application of ETYA (P < 0.01, n = 6 for 2F3 cell monolayers).

Inhibition of transepithelial open-circuit current by basolateral application of aristolochic acid was not reversed by the basolateral application of ETYA. This differs from the effect of ETYA on the increase in current observed with apical application of aristolochic acid (see Fig. 5). Figure 7B shows the results when ETYA is added to the basolateral media subsequent to basolateral aristolochic acid application. Control open-circuit current was 3.8 ± 0.2 µA/cm2. Current was reduced to 1.8 ± 0.1 µA/cm2 with a 10-min basolateral application of aristolochic acid. Subsequently, a 2-min application of basolateral ETYA (40 µM) significantly reduced currents further to 1.0 ± 0.06 µA/cm2 (P < 0.01). This indicates that the inhibition of current seen with basolateral application of aristolochic acid is not due to free fatty acid and implies that a metabolic product of AA may be involved in maintaining transepithelial transport.2

The effect of basolateral application of aristolochic acid was also measured under short-circuit current conditions and is shown in Fig. 8. The results did not differ from those observed in the open-circuit conditions (Fig. 7A). Current began at 27 ± 6 µA/cm2 for both control and experimental groups. Unlike the open-circuit current conditions, current level under short-circuit current was maintained throughout the experiment for the control group (26 ± 6 µA/cm2 at 10 min). Addition of basolateral aristolochic acid (200 µM) resulted in a marked decrease in short-circuit current, with a significant decrease clearly observed at 2 min (P < 0.05) and a large decrease observed at 10 min, 7 ± 2 µA/cm2 with aristolochic acid vs. 26 ± 6 µA/cm2 for the control group. Addition of 1 × 10-5 M amiloride reduced currents to similar levels of 4.2 ± 0.9 and 4.1 ± 0.9 µA/cm2 for control and experimental groups, respectively.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 8.   Short-circuit measurement of transepithelial current with basolateral application of 200 µM aristolochic acid (black-down-triangle ). Current from untreated monolayers is shown (). Basolateral aristolochic acid application produced a significant inhibition of transepithelial current within 2 min of addition (P < 0.05) and more substantial inhibition at 10 min (P < 0.001). Addition of 1 × 10-5 amiloride (last data point, past 10 min) reduced transepithelial current to near 0. For each group, n = 4 A6 cell monolayers.

Perhaps the most probable AA metabolite to mediate support of transepithelial transport is the cyclooxygenase product of AA, PGE2. Chronic application of basolateral PGE2 has been reported to increase Na+ channel number in the apical membrane of frog skin (17) and in A6 cells (27, 30). If PGE2 was necessary for transport, then inhibition of cPLA2 might produce an inhibition of transport as observed in Figs. 7 and 8, and the current inhibition should be prevented by the addition of exogenous PGE2 to the basolateral side of the monolayer. Such experiments are summarized in Fig. 9. Open-circuit current was measured under three conditions: basolateral aristolochic acid alone, basolateral PGE2 alone, and simultaneous application of basolateral aristolochic acid and PGE2. Starting currents were 3.2 ± 1.2 µA/cm2 for each group. As shown previously, basolateral application of aristolochic acid led to a significant reduction in transepithelial current (1.6 ± 0.2 µA/cm2 at 15 min). The basolateral application of 10 µM PGE2 alone resulted in the stimulation of transepithelial current (5.8 ± 0.2 µA/cm2 at 5 min). The addition of basolateral PGE2 with basolateral aristolochic acid prevented the basolateral inhibition of transepithelial current caused by basolateral aristolochic acid application alone. Current levels in the presence of both basolateral PGE2 and aristolochic acid were 4.8 ± 0.3 at 5 min and 6.7 ± 0.5 µA/cm2 at 15 min.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 9.   Inhibition of open-circuit transepithelial current by basolateral application of aristolochic acid is prevented by basolateral application of prostaglandin E2 (PGE2). A: transepithelial current measured with basolateral application of aristolochic acid (at time 0, darker circles), basolateral PGE2 (at time 0, triangles), or both aristolochic acid and PGE2 (at time 0, lighter circles). Basolateral PGE2 alone increased transepithelial current (P < 0.01) and was able to prevent the inhibition of current with basolateral application of aristolochic acid (P < 0.001, 15-min time point). For each group, n = 6 2F3 monolayers. B: basolateral application of the cyclooxygenase inhibitor ibuprofen (at time 0, triangles) inhibits current to a similar degree as does basolateral application of aristolochic acid (at time 0, circles). Both effects are reversed by basolateral application of PGE2 (arrow, at 5 min). For each group, n = 6 2F3 monolayers.

Direct inhibition of cyclooxygenase by basolateral ibuprofen leads to an inhibition of transepithelial open-circuit current similar to that seen with cPLA2 inhibition by basolateral aristolochic acid (Fig. 9B). Starting currents were 5.2 ± 0.2 µA/cm2 for each group. Transepithelial current was reduced to 3.5 ± 0.2 and 2.9 ± 0.2 µA/cm2 with basolateral application of aristolochic acid or ibuprofen, respectively. Current reduction in both cases was reversed with basolateral addition of 10 µM PGE2. Current 5 min after basolateral PGE2 was 4.8 ± 0.3 µA/cm2 in monolayers treated with basolateral aristolochic acid and 6.6 ± 0.4 µA/cm2 for monolayers treated with basolateral ibuprofen. The difference in current magnitude after PGE2 application is interesting and is addressed in DISCUSSION.

Combined effect of cPLA2 inhibition from the apical side and basolateral PGE2 addition. The increase in transepithelial current observed with the apical application of aristolochic acid is additive, with the stimulation of current observed with the basolateral application of PGE2. Figure 10 shows transepithelial open-circuit current measurements from monolayers treated simultaneously with apical aristolochic acid (200 µM) and basolateral PGE2 (10 µM). Starting current was 8.9 ± 0.3 µA/cm2. Combined application of apical aristolochic acid and basolateral PGE2 resulted in a peak increase in current of 21.2 ± 1.3 µA/cm2 at 10 min. Peak current magnitudes observed with apical application of aristolochic acid alone (Fig. 1A) were 14.2 ± 0.6 µA/cm2, whereas those observed with basolateral PGE2 were 6.7 ± 0.5 µA/cm2 (Fig. 9, A and B). The sum of these current magnitudes, 20.9 µA/cm2, is not significantly different from the 21.2 ± 1.3 µA/cm2 observed in Fig. 10.


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 10.   The combination of apical aristolochic acid and basolateral PGE2 produces an additive effect on transepithelial open-circuit current. Apical application of aristolochic acid produced a current level of 14.2 ± 0.6 µA/cm2 (see Fig. 1A). Basolateral application of PGE2 produced a current level of 6.7 ± 0.5 µA/cm2 (see Fig. 9A). In combination, current levels, as shown in this figure, peaked at 21.2 ± 1.3 µA/cm2 (n = 6 2F3 monolayers). The combined effect is not significantly different from the sum of the individual effects.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The data presented demonstrate that cPLA2 is tonically active in transporting A6 cells and that this activity is necessary for the support of transepithelial transport. Interestingly, however, a sidedness to cPLA2 inhibition results in a divergent effect on transepithelial transport, with inhibition from the apical side resulting in an increase in current and inhibition from the basolateral side resulting in a decrease in current. The increase in transepithelial current observed with apical side inhibition of cPLA2 results from the downmodulation of ENaC by free AA. The decrease in transepithelial current observed with basolateral side inhibition of cPLA2 results in part from a decrease in the metabolic product of AA, PGE2. Furthermore, the sidedness of cPLA2 inhibition suggests there is a local apical membrane-associated pool of cPLA2 at or near the apical Na+ channel in addition to commonly found perinuclear and endoplasmic reticular localization of cPLA2. These data provide a novel and intriguing mechanism whereby transepithelial Na+ transport and thus fluid reabsorption can be modulated over a relatively rapid time course, as well as provide for differential modulation by apical or basolateral signaling mechanisms.

The apical effect. Free AA or free unsaturated fatty acids have been shown to affect a number of ion channels (31), producing either an increase (11, 12, 39) or a decrease (23) in single channel Po. The data presented herein not only demonstrates that free fatty acid reduces the Po of the apical Na+ channel, ENaC, but also shows that under normal conditions of transport (e.g., aldosterone stimulated), free AA is produced at the apical membrane and exerts a downmodulatory effect on ENaC, thus slowing transport. Inhibition of cPLA2, by aristolochic acid from the apical side of transporting A6 cell monolayers, produced an approximate twofold increase in transepithelial Na+ transport and a 58% decrease in the rate of AA liberated at the apical membrane. Apical ETYA reversed the stimulatory effect of apical aristolochic acid on transepithelial current, indicating that free AA itself was acting to downmodulate transport at the apical membrane. Although apical AA application produced similar results (not shown), these results were more variable and could be misleading due to cellular metabolism of AA into a variety of signaling molecules. ETYA provided an advantage in that it is an analog of AA and has similar effects on ion channels as AA (12); however, ETYA is not subject to cellular metabolism. Apical ETYA might also inhibit PGE2 production, resulting in a reduction of current as with the basolateral effect of aristolochic acid or ibuprofen. However, if this were the principal means of the apical ETYA reduction of current, one would not expect current inhibition by AA or an additive effect of basolateral PGE2 and apical aristolochic acid as is observed. In single channel recordings, ETYA reduced the Po of ENaC. The reduction in ENaC activity with ETYA supports the notion that tonic production of free AA at or near the apical membrane downmodulates ENaC activity and thus transepithelial transport of Na+. The fact that an increase in transepithelial transport is observed with the inhibition of cPLA2 from the apical side supports the presence of tonically active cPLA2 at or near the apical Na+ channel in the transporting A6 cells. Alternatively, AA liberated at a locale distant to ENaC within the cell might be responsible for downmodulation of ENaC activity. This alternative hypothesis is less likely because inhibition of cPLA2 by basolateral application of aristolochic acid does not produce the same affect as apical application.

The basolateral effect. Inhibition of cPLA2 from the basolateral side of the A6 cell monolayer produced an effect on transepithelial current that was opposite from inhibition from the apical side. Basolateral application of aristolochic acid produced an inhibition of transepithelial current with a time course somewhat slower than that which was observed for the increase in current with apical aristolochic acid. Unlike that of the apical side effect, ETYA did not relieve the inhibition of current seen with basolateral side inhibition of cPLA2 but rather led to a greater inhibition of current. This effect of ETYA is consistent with the notion that free AA is tonically produced within the cell and is being metabolized to products that act to support transepithelial transport. Basolateral addition of the cyclooxygenase product of AA metabolism, PGE2, was able to prevent as well as reverse the inhibitory effect of basolateral aristolochic acid application. In support of PGE2 involvement, basolateral application of the cyclooxygenase inhibitor, ibuprofen, produced transepithelial current inhibition similar to that of aristolochic acid. The effect of ibuprofen was also reversed by the addition of PGE2. Interestingly, PGE2 produced a more robust response subsequent to ibuprofen than subsequent to aristolochic acid. Inhibition of cPLA2 would result in a decrease in all metabolic products of AA, whereas cyclooxygenase inhibition would only decrease prostaglandin production. Thus the more robust response with PGE2 after ibuprofen may indicate the involvement of other AA metabolites involved in the support of transport. Indeed, the lipoxygenase product of AA, LTD4, has been shown to increase Na+ channel activity in A6 cells (8).

The inhibitory effect on transport by basolateral side inhibition of cPLA2 supports the notion that cPLA2 within transporting A6 cells is active, and along with cyclooxygenase activity, is necessary to support Na+ transport. Indeed, basolateral PGE2 has previously been shown to increase short-circuit current and Na+ conductance in A6 cells (27, 30) and frog skin (17).

Model for the divergent effect. The divergent effect on transepithelial current with inhibition of cPLA2 from the apical and basolateral sides suggests discrete intracellular pools of cPLA2. Although cPLA2 has predominately been localized to the perinuclear and endoplasmic reticular membranes within cells (35), several studies have reported evidence that suggests that cPLA2 also can occur at the plasma membrane in confluent bovine endothelial cells (36), in fibroblasts (7), in glomerular epithelial cells (28), and in bradykinin-stimulated Madin-Darby canine kidney cells (26). Perhaps the most convincing evidence for cPLA2 presence in the plasma membrane derives from inside-out patch-clamp experiments in GH3 cells, where functionally, cPLA2 occurs in the same membrane patch as the Ca2+-activated K+ channel (BK channel) (14). Ion channels occur in the plasma membrane at relatively low abundance. At minimum, if one cPLA2 was associated with one BK channel, one might expect the plasma membrane abundance of cPLA2 to also be relatively low, particularly compared with the nuclear envelope.

A receptor-coupled apical membrane-situated cPLA2 could act as the transduction mechanism for intraluminal signaling molecules. The stimulation of Cl- current in colonic epithelia by 5'-(N-ethylcarboxamido)adenosine (an adenosine analog) was found to correlate with the release of [3H]AA and was abolished by the PLA2 inhibitor 4-bromophenacyl bromide, suggesting that adenosine was acting by increasing PLA2 activity, and the resulting free AA was affecting transepithelial Cl- current (1). Similarly, Smallridge and Gist (38) have shown that the ATP stimulation of 125I- efflux in the thyroid cell line FRTL-5 was correlated with an increased release of [3H]AA, both of which were abolished by the PLA2 inhibitor U-73122. It is interesting to think of these results in light of the connection between ATP, Cl- secretion, and Na+ reabsorption, where it is speculated that external ATP, somehow dependent on active cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel, acts to inhibit Na+ reabsorption and the Na+ channel (15). Endothelin-1 has also been shown to increase free AA levels (24) in smooth muscle and to affect Na+ transport in epithelia (20). The emerging precedence from these data suggests that receptor-mediated signaling through cPLA2 and AA release can have an effect on ion transport processes. Receptors to adenosine, ATP, and endothelin-1 have been identified in renal collecting duct epithelia either directly (10, 16, 34, 37) or by inference from pharmacological effects (see below). Moreover, as might be expected for intratubular signaling, adenosine, ATP, and endothelin-1 are present in normal urine and have been shown to vary during certain pathological conditions (24, 32). Their occurrence, particularly in the cases of adenosine and endothelin-1, are proposed to protect against ischemic damage by inhibiting the transport of Na+ (2, 6, 18). As briefly mentioned earlier, the amiloride-sensitive Na+ channel is inhibited by extracellular ATP, the level of which is partially determined by CFTR activity (15), thus allowing for cellular self-regulation of apical Na+ reabsorption. Additionally, apical application of adenosine in A6 cells, via a type A2 receptor, produces an inhibition of Na+ channel activity (29). Basolateral application of adenosine, on the other hand, produces an increase in Na+ transport (9). Endothelin-1 applied basolaterally, most likely ETA receptor mediated, also produces a stimulation of apical Na+ channel activity (20), thus suggesting a precedence that compounds, which may act through cPLA2, produce opposite effects when applied to the apical membrane vs. the basolateral membrane. Studies that determine the effects and dependence of apical agonists on cPLA2 activity, free AA release at the apical membrane, and Na+ channel activity are currently under way.

On the basis of the data presented, we propose that 1) AA from cPLA2 activity at or near the apical membrane is primarily responsible for downmodulation of transepithelial current, and 2) AA from cPLA2 activity combined with cyclooxygenase activity within the cell, presumably perinuclear, produces PGE2, which is necessary to support transport. Together, the apical effect of AA downmodulation of ENaC and the necessity of the AA product PGE2 to support transport provide a cellular signaling mechanism to fine-tune Na+ transport, based on the relative activity of cPLA2 at the apical membrane and the perinuclear cPLA2 and cyclooxygenase activity. With fixed cPLA2 activity, manipulation of cyclooxygenase activity would result in relative changes of free AA. With greater cyclooxygenase activity, more PGE2 would be produced, resulting in less free AA, which would tend to maximize transport. In contrast, less cyclooxygenase activity would yield less PGE2 and result in more free AA, which would tend to minimize transport. Increased cPLA2 activity at or near the apical membrane would tend to decrease transport, whereas increased cPLA2 near an active cyclooxygenase enzyme would tend to increase transport. Indeed, as early as 1975, an increased phospholipid turnover was suggested to occur with stimulation of Na+ transport in toad bladder (22). This increase was attributed to cellular increase in phospholipase activity (42). This report provides further evidence as well as a model for the increased rate of phospholipid turnover and establishes the increased turnover as important in the regulation of Na+ transport. Specifically, AA and PGE2 act in an antagonistic manner in A6 cells to modulate Na+ transport rate.


    ACKNOWLEDGEMENTS

We are grateful to B. J. Duke for plating and maintaining the 2F3 cell cultures. All short-circuit current experiments were made in the laboratory of Bonnie Blazer-Yost (Dept. of Biology, Indiana Univ. Purdue Univ. at Indianapolis). We are most appreciative of her support in providing equipment and the expertise of her laboratory personnel, Carla J. Faletti, Amy Hartman, and Diane Hoover. Without this support, the short-circuit current measurements would have been much more difficult.


    FOOTNOTES

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant DK-09215 (to R. T. Worrell), National Science Foundation Grant IBN-9603837 (to D. D. Denson), NIDDK Grants DK-37963 and DK-50268 (to D. C. Eaton), and by the Center for Cell and Molecular Signaling at Emory.

Address for reprint requests and other correspondence: R. T. Worrell, Dept. of Physiology, Center for Cell and Molecular Signaling, Emory Univ., Atlanta, Georgia 30322 (E-mail: rworrel{at}emory.edu).

1  It is interesting to note that long-term (>15-20 min) application of aristolochic acid to the apical side also resulted in an inhibition of transepithelial current subsequent to current stimulation. The most likely explanation is that aristolochic acid is diffusing through or across the cell and reaching the sites that are more readily accessible from the basolateral membrane (the basolateral effect but with a lag time to the onset). All apical application experiments were performed with <10 min of aristolochic application to avoid this secondary effect. Transepithelial current increase was never observed subsequent to the decrease in current with basolateral aristolochic acid, thus suggesting a necessity for cPLA2 activity in the support of transport.

2  Experiments with basolateral ETYA alone also produced inhibition of current similar to basolateral aristolochic acid. This arises from ETYA inhibition of the enzymes that metabolize AA (i.e., cyclooxygenase). ETYA was used in this experiment as a means of distinguishing between a free fatty acid effect vs. an AA metabolite effect.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 29 June 2000; accepted in final form 14 February 2001.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Barrett, KE, and Bigby TD. Involvement of arachidonic acid in the chloride secretory response of intestinal epithelial cells. Am J Physiol Cell Physiol 264: C446-C452, 1993[Abstract/Free Full Text].

2.   Beach, RE, and Good DW. Effects of adenosine on ion transport in rat medullary thick ascending limb. Am J Physiol Renal Fluid Electrolyte Physiol 263: F482-F487, 1992[Abstract/Free Full Text].

3.   Blazer-Yost, BL, Fesseha Y, and Cox M. Aldosterone mediated Na+ transport in renal epithelia: time course of induction of a potential regulatory component of the conductive Na+ channel. Biochem Int 26: 887-897, 1992[ISI][Medline].

4.   Blazer-Yost, BL, Paunescu TG, Helman SI, Lee KD, and Vlahos CJ. Phosphoinositide 3-kinase is required for aldosterone-regulated sodium reabsorption. Am J Physiol Cell Physiol 277: C532-C536, 1999.

5.   Bonventre, JV. Phospholipase A2 and signal transduction. J Am Soc Nephrol 3: 128-150, 1992[Abstract].

6.   Brezis, M, Rosen S, Silva P, and Epstein FH. Transport activity modifies thick ascending limb damage in the isolated perfused kidney. Kidney Int 25: 65-72, 1984[ISI][Medline].

7.   Bunt, G, de Wit J, van den Bosch H, Verkleij AJ, and Boonstra J. Ultrastructural localization of cPLA2 in unstimulated and EGF/A23187-stimulated fibroblasts. J Cell Sci 110: 2449-2459, 1997[Abstract/Free Full Text].

8.   Cantiello, HF, Patenaude CR, Codina J, Birnbaumer L, and Ausiello DA. Galpha i-3 regulates epithelial Na+ channels by activation of phospholipase A2 and lipoxygenase pathways. J Biol Chem 265: 21624-21628, 1990[Abstract/Free Full Text].

9.   Casavola, V, Guerra L, Reshkin SJ, Jacobson KA, Verrey F, and Murer H. Effect of adenosine on Na+ and Cl- currents in A6 monolayers. Receptor localization and messenger involvement. J Membr Biol 151: 237-245, 1996[ISI][Medline].

10.   Chan, CM, Unwin RJ, Bardini M, Oglesby IB, Ford APDW, Townsend-Nicholson A, and Burnstock G. Localization of P2X1 purinoceptors by autoradiography and immunohistochemistry in rat kidneys. Am J Physiol Renal Physiol 274: F799-F804, 1998[Abstract/Free Full Text].

11.   Cuppoletti, J. Possible role of ion channels in the action of nonsteroidal anti-inflammatory drugs. News Physiol Sci 15: 106, 2000[Free Full Text].

12.   Denson, DD, Wang X, Worrell RT, and Eaton DC. Effects of fatty acids on BK channels in GH3 cells. Am J Physiol Cell Physiol 279: C1211-C1219, 2000[Abstract/Free Full Text].

13.   Denson, DD, Worrell RT, and Eaton DC. A possible role for phospholipase A2 in the action of general anesthetics. Am J Physiol Cell Physiol 270: C636-C644, 1996[Abstract/Free Full Text].

14.   Denson, DD, Worrell RT, Middleton P, and Eaton DC. Ca2+ sensitivity of BK channels in GH3 cells involves cytosolic phospholipase A2. Am J Physiol Cell Physiol 276: C201-C209, 1999[Abstract/Free Full Text].

15.   Devidas, S, and Guggino WB. The cystic fibrosis transmembrane conductance regulator and ATP. Curr Opin Cell Biol 9: 547-552, 1997[ISI][Medline].

16.   Edwards Trizna, RMW, and Stack EJ. [125I]-endothelin-1 binding to renal brush border and basolateral membranes. Eur J Pharmacol 345: 229-232, 1998[ISI][Medline].

17.   Els, WJ, and Helman SI. Dual role of prostaglandins (PGE2) in regulation of channel density and open probability of epithelial Na+ channels in frog skin (R. pipiens). J Membr Biol 155: 75-87, 1997[ISI][Medline].

18.   Franco, M, Bell PD, and Navar LG. Effect of adenosine A1 analog on tubuloglomerular feedback mechanism. Am J Physiol Renal Fluid Electrolyte Physiol 257: F231-F236, 1989[Abstract/Free Full Text].

19.   Funder, JW. Aldosterone action. Annu Rev Physiol 55: 115-130, 1993[ISI][Medline].

20.   Gallego, MS, and Ling BN. Regulation of amiloride-sensitive Na+ channels by endothelin-1 in distal nephron cells. Am J Physiol Renal Fluid Electrolyte Physiol 271: F451-F460, 1996[Abstract/Free Full Text].

21.   Garty, H, and Palmer LG. Epithelial sodium channels: function, structure, and regulation. Physiol Rev 77: 359-396, 1997[Abstract/Free Full Text].

22.   Goodman, DB, Wong M, and Rasmussen H. Aldosterone-induced membrane phospholipid fatty acid metabolism in the toad urinary bladder. Biochemistry 14: 2803-2809, 1975[ISI][Medline].

23.   Hwang, TC, Guggino SE, and Guggino WB. Direct modulation of chloride channels by arachidonic and other cis unsaturated fatty acids. Proc Natl Acad Sci USA 87: 5706-5709, 1990[Abstract].

24.   Jones, AW, Magliola L, Waters CB, and Rubin LJ. Endothelin-1 activates phospholipases and channels at similar concentrations in porcine coronary arteries. Am J Physiol Cell Physiol 274: C1583-C1591, 1998[Abstract/Free Full Text].

25.   Kemendy, AE, Kleyman TR, and Eaton DC. Aldosterone alters the open probability of amiloride-blockable sodium channels in A6 epithelia. Am J Physiol Cell Physiol 263: C825-C837, 1992[Abstract/Free Full Text].

26.   Kennedy, C, Proulx PR, and Herbert RL. Bradykinin-induced translocation of cytoplasmic phospholipase A2 in MDCK cells. Can J Physiol Pharmacol 75: 563-567, 1997[ISI][Medline].

27.   Kokko, KE, Matsumoto PS, Ling BN, and Eaton DC. Effects of prostaglandin E2 on amiloride-blockable Na+ channels in a distal nephron cell line (A6). Am J Physiol Cell Physiol 267: C1414-C1425, 1994[Abstract/Free Full Text].

28.   Liu, J, Takano T, Papillon J, Khadir A, and Cybulsky AV. Cytosolic phospholipase A2-alpha associates with plasma membrane, endoplasmic reticulum and nuclear membrane in glomerular epithelial cells. Biochem J 353: 79-90, 2001[ISI][Medline].

29.   Ma, H, and Ling BN. Luminal adenosine receptors regulate amiloride-sensitive Na+ channels in A6 distal nephron cells. Am J Physiol Renal Fluid Electrolyte Physiol 270: F798-F805, 1996[Abstract/Free Full Text].

30.   Matsumoto, PS, Mo L, and Wills NK. Osmotic regulation of Na+ transport across A6 epithelium: interactions with prostaglandin E2 and cyclic AMP. J Membr Biol 160: 27-38, 1997[ISI][Medline].

31.   Meves, H. Modulation of ion channels by arachidonic acid. Prog Neurobiol 43: 175-186, 1994[ISI][Medline].

32.   Miller, WL, Thomas RA, Berne RM, and Rubio R. Adenosine production in the ischemic kidney. Circ Res 43: 390-397, 1978[Abstract].

33.   Murakami, M, Nakatani Y, Atsumi G, Inoue K, and Kudo I. Regulatory functions of phospholipase A2. Crit Rev Immunol 17: 225-283, 1997[ISI][Medline].

34.   Nord, EP. Renal actions of endothelin. Kidney Int 44: 451-463, 1993[ISI][Medline].

35.   Peters-Golden, M, Song K, Marshall T, and Brock T. Translocation of cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis. Biochem J 318: 797-803, 1996[ISI][Medline].

36.   Sierra-Honigmann, MR, Bradley JR, and Pober JS. "Cytosolic" phospholipase A2 is in the nucleus of subconfluent endothelial cells but confined to the cytoplasm of confluent endothelial cells and redistributes to the nuclear envelope and cell junctions upon histamine stimulation. Lab Invest 74: 684-695, 1996[Medline].

37.   Simonson, MS, and Dunn MJ. Endothelin peptides and the kidney. Annu Rev Physiol 55: 249-265, 1993[ISI][Medline].

38.   Smallridge, RC, and Gist ID. P2-purinergic stimulation of iodide efflux in FRTL-5 rat thyroid cells involves parallel activation of PLC and PLA2. Am J Physiol Endocrinol Metab 267: E323-E330, 1994[Abstract/Free Full Text].

39.   Stockand, JD, Silverman M, Hall D, Derr T, Kubacak B, and Sansom SC. Arachidonic acid potentiates the feedback response of mesangial BKCa channels to angiotensin II. Am J Physiol Renal Physiol 274: F658-F664, 1998[Abstract/Free Full Text].

40.   Verrey, F. Transcriptional control of sodium transport in tight epithelia by adrenal steroids. J Membr Biol 144: 93-110, 1995[ISI][Medline].

41.   Vishwannath, BS, and Gowda TV. Interaction of aristolochic acid with Vipera russelli phospholipase A2: its effect on enzymatic and pathological activities. Toxicon 25: 929-937, 1987[ISI][Medline].

42.   Yorio, T, and Bentley PJ. Phospholipase A and the mechanism of action of aldosterone. Nature 271: 79-91, 1978[ISI][Medline].


Am J Physiol Cell Physiol 281(1):C147-C156
0363-6143/01 $5.00 Copyright © 2001 the American Physiological Society